Resmonics
Respiratory disease monitoring using clinically validated biomarkers
Tell Me More

Resmonics presents:

RESGUARD MED

Our first product, ResGuard Med, turns a patient’s smartphone into a guardian angel at night. It protects patients from life-threatening asthma attacks and helps them to stay in control of their disease. The only thing patients need to do is to place their smartphones in their bedroom at night.

ResGuard Med closes an important gap in today’s patient journey: a disease monitoring tool that is truly compatible with everyday life. This is how ResGuard Med works:

Keep the smartphone in your bedroom

ResGuard Med monitors symptoms at night.
Automatically and passively.

Enjoy your newly won peace of mind

In times of medical necessity, we will alert you.
No risk, no alerts.

Explore novel and unique disease insights

We enrich your subjective disease assessments.
With objective facts.

Technology

Strong claims require strong evidence. Our products are based on five years of deep learning and respiratory medicine research. Explore our growing evidence base by browsing through an excerpt of our peer-reviewed papers and posters.

24/7 Cough Monitoring in Hospitalized Covid-19 Patients

Swiss MedTech Day 2020

Nocturnal cough and sleep quality as markers for asthma

Journal of Asthma and Allergy 2020

Deep learning cough detection in real-world asthma

JMIR 2020

Characteristics of nocturnal cough in asthma

Journal of Asthma and Allergy 2020

Deep learning breathing pattern detection

UbiComp 2019

Device-agnostic cough detection with deep learning

IEEE ICHI 2019

Nocturnal cough and sleep quality as markers for asthma

BMJ Open

Systematic review of publicly available asthma apps

JMIR mhealth and uhealth

Enhancing asthma control through IT (mHealth)

WI Conference

Featured News

  1. Resmonics wins
    Venture Kick II
  2. Financing round
    closed
  3. Selected for the Swiss
    Startup National Team
  4. Resmonisc wins
    Venture Kick III

  1. CHF 40,000 for startups developing oral microbiome therapies to treat chronic kidney disease and solutions to monitor asthma

    November 24th, 2020

    Resmonics win Venture Kick's second stage of financial and entrepreneurial support. Their project helps patients monitor their asthma at night and prevent attacks. Read More

  2. Respiratory Health Tech Startup Resmonics Closes its Pre-Seed Financing Round

    January 10th, 2021

    Zurich, Switzerland, January 19th, 2021 – Recently incorporated digital biomarker startup Resmonics has received financial support from the CSS insurance in its pre-seed financing round. The due diligence was conducted by Redstone on behalf of CSS Insurance. The funding will be used to accelerate the development of its first product, a smartphone-based digital biomarker service for patients suffering from asthma or COPD, and to certify it as a medical device. ... Read More

  3. Resmonics got selected for the Venture Leaders Mobile National Team

    April 16th, 2021

    The jury of Venture Leaders Mobile 2021 selected 10 start-ups. They represent a range of sectors from digital health to insurtech and advance innovations in artificial intelligence, big data, or blockchain. The selected teams will travel to Barcelona to attend the Mobile World Congress from June 28–July 1, 2021, planned as an in-person event with hybrid experiences. Read More

  4. Resmonics wins CHF 150,000 to turn the smartphones of patients with chronic respiratory diseases into guardian angels

    June 23rd, 2021

    Resmonics win Venture Kick's final stage of financial and entrepreneurial support. Their first product, ResGuard Med, is a CE-certified early-warning system that helps patients with chronic respiratory diseases manage their condition. Read More

Meet the team

Our core value is to develop innovative technology to improve patients' everyday lives. We operate at the intersection of respiratory medicine, artificial intelligence, and business innovation.

“My MSc in psychology and years of research experience in digital health made me realize that it is often more worthwhile to change technology than human behavior, in particular in chronic care.”

Dr. Peter Tinschert

Co-Founder, CEO

“My PhD and my computer science degree taught me how to build state-of-the-art tech. What excites me the most, however, is when technology actually improves patient lives in the real world.”

Dr. Iris Shih

Co-Founder, CTO

Kai Habighorst

Head of Product Management

Ihor Khomich

Senior iOS Developer

Interested in Resmonics? Contact Us!

We would love to get in contact with you!